Mouse model with hypothyroidism and pulmonary arterial hypertension as well as construction method and application of mouse model

By gasifying methimazole and injecting vascular endothelial growth factor inhibitor Su5416 in mice and feeding under hypoxia environment, a mouse model of hypothyroidism and pulmonary hypertension was successfully constructed, solving the lack of this type in the prior art The problem of the model provides an experimental platform for studying the effects of hypothyroidism on pulmonary hypertension.

CN118947636AActive Publication Date: 2024-11-15SICHUAN ACADEMY OF MEDICAL SCI SICHUAN PROVINCIAL PEOPLES HOSPITAL

Patent Information

Application Number
CN202411358879.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-27
Publication Date
2024-11-15
Estimated Expiration
2044-09-27

AI Technical Summary

Technical Problem

The existing animal experimental models lack the simulation of hypothyroidism combined with pulmonary hypertension, and cannot effectively study the mechanisms and treatment methods of this complex disease.

Method used

By gasifying methimazole in mice and feeding under normal oxygen environment, followed by continuous subcutaneous injection of vascular endothelial growth factor inhibitor Su5416 and feeding under hypoxia environment, a mouse model of hypothyroidism and pulmonary hypertension was successfully constructed. .

Benefits of technology

A stable mouse model of hypothyroidism combined with pulmonary hypertension was established for pathological studies and drug testing, providing a reliable experimental platform to study the effects of hypothyroidism on pulmonary hypertension.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118947636A_ABST
    Figure CN118947636A_ABST
Patent Text Reader

Abstract

The invention provides a hypothyroidism combined pulmonary arterial hypertension mouse model and a construction method and application thereof, and belongs to the technical field of animal experiment model construction. The method comprises the following steps of: performing intragastric administration on methimazole in a mouse body, and feeding in a normal oxygen environment to obtain a hypothyroidism mouse model; and continuously performing intragastric administration on the hypothyroidism mouse model with methimazole, continuously performing subcutaneous injection on a vascular endothelial growth factor inhibitor Su5416, and feeding in a low-oxygen environment to obtain the hypothyroidism combined pulmonary hypertension mouse model. The stable hypothyroidism combined pulmonary hypertension mouse model is successfully established in a mode of combining drug intervention and hypoxia feeding.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of constructing animal experimental models, and in particular relates to a mouse model of hypothyroidism combined with pulmonary hypertension, and a construction method and application thereof. Background Art

[0002] Hypothyroidism, commonly known as hypothyroidism, is a systemic hypometabolic syndrome caused by a weakened production or action of thyroid hormones due to various reasons. The most common causes of this disease are autoimmune diseases, drugs, surgery, etc., which lead to insufficient production or utilization of thyroid hormones. Hypothyroidism often develops insidiously and has a long course. Many patients lack specific symptoms for a long time. As the disease progresses, it may become progressively worse, with systemic symptoms such as chills and fatigue. When the heart is involved, pericardial effusion and heart failure may occur, and severe patients may develop myxedema coma.

[0003] Pulmonary hypertension refers to a hemodynamic and pathophysiological state in which the pulmonary artery pressure rises above a certain threshold, which can lead to right heart failure. It can be an independent disease, a complication, or a syndrome. Pulmonary hypertension can be divided into five categories: ① arterial pulmonary hypertension; ② pulmonary hypertension caused by left heart disease; ③ pulmonary hypertension caused by hypoxia and / or lung disease; ④ chronic thromboembolic pulmonary hypertension; ⑤ pulmonary hypertension caused by multiple mechanisms and / or unknown mechanisms. Common symptoms of pulmonary hypertension include dyspnea, fatigue, weakness, decreased exercise tolerance, syncope, chest pain, and leg and ankle edema.

[0004] In the 2016 guidelines issued by the European Society of Cardiology / Respiratory Society (ESC / ERS), thyroid disease was listed as one of the causes of Group 5 pulmonary hypertension (unclear mechanism and / or multifactorial pulmonary hypertension). According to observational studies, the prevalence of hypothyroidism in patients with pulmonary hypertension is estimated to be between 10% and 24%, which is significantly higher than that in the general population. In addition, studies have shown that pulmonary artery pressure and pulmonary vascular resistance in patients with hypothyroidism are higher than those in patients with normal thyroid function. More noteworthy is that patients with pulmonary hypertension with hypothyroidism have poorer cardiac function and poorer prognosis, and high TSH levels are associated with increased mortality in patients with pulmonary hypertension. The emergence of complications of hypothyroidism and pulmonary hypertension has attracted widespread attention in the medical community. Studies in recent years have gradually revealed the possible close connection between hypothyroidism and PH, but little is known about the specific mechanism of the effect of hypothyroidism on PH. Therefore, establishing a reliable animal model is an important part of conducting research on hypothyroidism with pulmonary hypertension. Currently available experimental animal models are only for hypothyroidism and pulmonary hypertension, and there is a lack of experimental animal models for hypothyroidism associated with pulmonary hypertension. Summary of the invention

[0005] In view of this, the object of the present invention is to provide a mouse model of hypothyroidism combined with pulmonary hypertension and a construction method and application thereof.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides a method for constructing a mouse model of hypothyroidism combined with pulmonary hypertension, comprising the following steps:

[0008] 1) The hypothyroidism mouse model was obtained by gavage of methimazole in mice and keeping them in a normoxic environment;

[0009] 2) The hypothyroidism mouse model was continued to be gavaged with methimazole, the vascular endothelial growth factor inhibitor Su5416 was continuously injected subcutaneously, and the mouse model with hypothyroidism and pulmonary hypertension was obtained by raising the mouse in a hypoxic environment.

[0010] Preferably, the mouse is a C57BL / 6 mouse.

[0011] Preferably, the intragastric administration amount of methimazole in step 1) is 30 to 50 mg / kg / d; the intragastric administration time of methimazole is 3 to 5 weeks.

[0012] Preferably, the intragastric administration amount of methimazole in step 2) is 30 to 50 mg / kg / d; and the intragastric administration time of methimazole is 3 to 4 weeks.

[0013] Preferably, the injection amount of the vascular endothelial growth factor inhibitor Su5416 in step 2) is 20 mg / kg / w.

[0014] Preferably, the vascular endothelial growth factor inhibitor Su5416 is injected for 3 to 4 weeks.

[0015] Preferably, the oxygen concentration of the hypoxic environment in step 2) is 9-11%.

[0016] The present invention also provides the use of the hypothyroidism combined with pulmonary hypertension mouse model constructed by the construction method in pathological research of hypothyroidism combined with pulmonary hypertension or in vitro drug testing and screening.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] The present invention successfully established a hypothyroidism model by continuously gavaging C57BL / 6 mice with methimazole, then cutting off the tail and collecting blood to detect thyroid function, followed by subcutaneous injection of vascular endothelial growth factor inhibitor Su5416, and raising them in a hypoxic environment to measure right ventricular systolic pressure by right cardiac catheterization, and cardiac ultrasound to detect pulmonary blood flow acceleration time and pulmonary blood flow ejection time to show that a pulmonary hypertension model was successfully established. The present invention successfully established a stable hypothyroidism combined with pulmonary hypertension mouse model by combining drug intervention and hypoxic feeding. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is a brief flow chart of the modeling process of the mouse model of hypothyroidism combined with pulmonary hypertension;

[0020] Figure 2 are the right ventricular waveform curves and right ventricular systolic pressure measurements of mice in different treatment groups (where A is the right ventricular pressure curve of mice in each group; B is the comparison of right ventricular systolic pressure (RVSP) of mice in each group, compared with the CON group, ** P<0.01; compared with SuHx group, ## P<0.01; compared with SuHx+MMI group, & P<0.05. );

[0021] Figure 3 are the PTA and PAT / PET values ​​measured by echocardiography of mice in different treatment groups (where A is the Doppler signal of pulmonary valve blood flow recorded at the level of the aorta in the short-axis section of the left ventricle by pulsed Doppler ultrasound, and the pulmonary blood flow acceleration time (PAT) and pulmonary blood flow ejection time (PET) were measured; B is the comparison of PAT values ​​of mice in each group; C is the comparison of PAT / PET values ​​of mice in each group, compared with the CON group, ** P<0.01; compared with SuHx group, # P<0.05, ## P<0.01; compared with SuHx+MMI group, & P<0.05. );

[0022] Figure 4 HE staining was used to observe the pulmonary vascular remodeling of mice in different treatment groups: pulmonary vessels of mice in each group under a microscope (200×, scale bar = 50 μm);

[0023] Figure 5 Masson staining was used to observe the pulmonary vascular fibrosis in each group of mice (200×, scale bar = 50 μm). DETAILED DESCRIPTION

[0024] The present invention provides a method for constructing a mouse model of hypothyroidism combined with pulmonary hypertension, comprising the following steps:

[0025] 1) The hypothyroidism mouse model was obtained by gavage of methimazole in mice and keeping them in a normoxic environment;

[0026] 2) The hypothyroidism mouse model was continued to be gavaged with methimazole, the vascular endothelial growth factor inhibitor Su5416 was continuously injected subcutaneously, and the mouse model with hypothyroidism and pulmonary hypertension was obtained by raising the mouse in a hypoxic environment.

[0027] In the present invention, mice are gavaged with methimazole and raised in a normoxic environment to obtain a hypothyroid mouse model. The mice are preferably C57BL / 6 mice; the gavage amount of methimazole is preferably 30 to 50 mg / kg / d, more preferably 40 mg / kg / d; the gavage time of methimazole is preferably 3 to 5 weeks, more preferably 4 weeks.

[0028] In the present invention, the hypothyroidism mouse model is continuously gavaged with methimazole and the vascular endothelial growth factor inhibitor Su5416 is continuously subcutaneously injected, the gavage amount of methimazole is preferably 30-50 mg / kg / d, more preferably 40 mg / kg / d; the gavage time of methimazole is preferably 3-4 weeks; the injection amount of the vascular endothelial growth factor inhibitor Su5416 is preferably 20 mg / kg / w; the injection time of the vascular endothelial growth factor inhibitor Su5416 is preferably 3-4 weeks; and the mouse model of hypothyroidism combined with pulmonary hypertension is obtained by raising the mouse in a hypoxic environment; the oxygen concentration of the hypoxic environment is preferably 9-11%, more preferably 10%.

[0029] The present invention also provides the use of the hypothyroidism combined with pulmonary hypertension mouse model constructed by the construction method in pathological research of hypothyroidism combined with pulmonary hypertension or in vitro drug testing and screening.

[0030] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0031] C57BL / 6 mice were purchased from the Experimental Animal Center of Gansu University of Chinese Medicine and were raised in the SPF-grade Animal Experimental Center of Gansu University of Chinese Medicine;

[0032] Mouse TSH ELISA kit, catalog number: E-EL-M1153C, was purchased from Eliorite Biotech Co., Ltd., Wuhan, China;

[0033] Mouse FT4 ELISA kit, catalog number: MM-202305, was purchased from Jiangsu ELISA Industrial Co., Ltd., China.

[0034] Example 1

[0035] 1. Construction of a model of hypothyroidism combined with pulmonary hypertension

[0036] 8-week-old male SPF C57BL / 6 mice were given methimazole (MMI) 40 mg / kg / d by oral gavage for 4 weeks, and then blood was collected from the tail to test thyroid function (serum TSH and FT4 levels). After the pulmonary hypertension model was successfully established, the vascular endothelial growth factor inhibitor Su5416 (20 mg / kg / w) was subcutaneously injected for 3 consecutive weeks. During this period, the mice were placed in a normal pressure hypoxia chamber with an oxygen concentration of 10%. A brief flowchart of the modeling process is shown below. Figure 1 shown.

[0037] The experiment was divided into 5 groups: CON, control group; SuHx, pulmonary hypertension group; MMI, hypothyroidism group; SuHx+MMI, pulmonary hypertension combined with hypothyroidism group; SuHx+MMI+L-T4, L-T4 intervention group.

[0038] 2. Signs of Successful Model Building

[0039] Hypothyroidism model: The serum TSH and FT4 levels were tested, and the results showed that the TSH level was significantly higher than that of the control group mice, and the FT4 level was significantly lower than that of the control group mice, indicating that the hypothyroidism model was successfully constructed.

[0040] Mouse model of hypothyroidism combined with pulmonary hypertension: right ventricular systolic pressure (RVSP) measured by right cardiac catheter was higher than that of control mice (gold standard); pulmonary artery acceleration time (PAT) and pulmonary ejection time (PET) were detected by cardiac ultrasound, and PAT / PET (PAT / PET was negatively correlated with pulmonary artery pressure) was calculated, which was lower than that of control mice. At the end of modeling, mice were killed and further observed by hematoxylin-eosin (HE) staining and Masson staining of lung tissue pathological sections, showing that the pulmonary vascular wall was thickened, the lumen was narrowed, and the collagen deposition of the vascular adventitia was increased compared with the control mice. Blood was collected from the eyeball to measure serum TSH and FT4 levels, and TSH was significantly higher than that of control mice, and FT4 was significantly lower than that of control mice. This is the mouse model of hypothyroidism combined with pulmonary hypertension.

[0041] 3. Thyroid function test

[0042] After the modeling is completed, the eyeballs of the mice are removed after anesthesia to collect blood. The blood of the mice is collected in a sterile tube and allowed to stand at room temperature for about 15 to 30 minutes to allow the blood to coagulate naturally. The coagulated blood is centrifuged at 4°C for 15 minutes (2000 rpm) to separate the serum and clots. The upper layer of serum is carefully aspirated into a sterile centrifuge tube with a pipette to avoid disturbing the red blood cells or clots in the lower layer, and stored at -80°C for later use.

[0043] 1. Detection of serum TSH concentration by enzyme-linked immunosorbent assay

[0044] (1) Take the test kit and serum samples out of the refrigerator 20 minutes before the test and place them at room temperature (18-25°C); dilute the concentrated washing solution with double distilled water (1:24); centrifuge the standard at 10,000×g for 1 minute, add 1 mL of standard & sample diluent, cover the tube and let it stand for 10 minutes, then mix thoroughly until the standard solution is dissolved to prepare a standard working solution of 80 ng / ml. Continue to prepare the following concentrations of standard solutions according to the instructions: 40, 20, 10, 5, 2.5, 1.25, 0 ng / mL; centrifuge the biotinylated antibody concentrate at 800×g for 1 minute, and then dilute it 100 times with biotinylated antibody diluent to a working concentration of 1×; centrifuge the HRP enzyme-conjugated concentrate at 800×g for 1 minute, and then dilute it 100 times with diluent to a working concentration of 1×.

[0045] (2) Operation steps: Set up standard wells, blank wells and sample wells respectively. Add 100 μL of standard solution to the standard wells, 100 μL of standard solution & sample diluent to the blank wells, and 100 μL of sample diluent to the remaining wells; then, cover with a plate film and incubate at 37°C for 90 minutes; after incubation, shake off the liquid in the wells without washing, then add 100 μL of biotinylated antibody working solution to each well and continue incubating at 37°C for 1 hour; after the incubation, shake off the liquid and pat dry on absorbent paper, fill each well with washing solution, soak for 1 minute, then shake off and pat dry, repeat this washing process 3 times; then add 100 μL of HRP enzyme conjugate working solution to each well, cover with a plate film, incubate at 37°C for 30 minutes, repeat washing 5 times; finally, add Add 90 μL of substrate solution (TMB), cover with a plate film, and incubate at 37°C in the dark for 15 minutes; turn on the microplate reader 15 minutes in advance for preheating. When an obvious gradient appears in the 4 color-developing wells before the standard well, add 50 μL of stop solution to each well. After the reaction is completed, quickly use the microplate reader to measure the OD value of each well at a wavelength of 450 nm; then, based on the known concentration of the standard and its corresponding OD value, draw a standard curve, and further calculate a linear regression equation; substitute the OD value of the sample to be tested into the equation, and the concentration of the sample can be calculated; finally, after the corresponding dilution multiple conversion, the exact concentration of TSH in the sample can be obtained.

[0046] 2. Detection of serum FT4 concentration by enzyme-linked immunosorbent assay

[0047] (1) Take out the serum sample and ELISA kit from the refrigerator and place them at room temperature for half an hour; dilute the concentrated washing solution 30 times with distilled water.

[0048] (2) Prepare the following concentrations of standard samples according to the kit instructions: 12, 6, 3, 1.5, 0.75, and 0 pmol / L.

[0049] (3) Blank wells, standard wells, and wells for samples to be tested are set up separately. No sample or enzyme-labeled reagent is added to the blank well, and the rest of the operations are the same as those for other wells. For the standard well, 50 μL of standard solution is added. For the wells for samples to be tested, 40 μL of sample diluent is first added, followed by 10 μL of sample, to ensure that the final dilution factor of the sample reaches 5 times.

[0050] (4) Seal the plate with sealing film and incubate at 37°C for 30 minutes.

[0051] (5) Remove the sealing film, shake off the liquid, fill each well with detergent, let it stand for 30 seconds, and then discard the liquid. Repeat this process 5 times and pat dry.

[0052] (6) Add 50uL of enzyme-labeled reagent to each well, except for the blank well; repeat step ⑤.

[0053] (7) First add 50 μL of colorimetric reagent A to each well, then add 50 μL of colorimetric reagent B. Gently shake to mix well, and incubate at 37°C in the dark for 10 minutes.

[0054] (8) Measure the OD value of each well at a wavelength of 450 nm using an ELISA reader. A linear regression equation was established using the standard concentration and OD value. The sample OD value was substituted into the equation to calculate the concentration, which was then multiplied by the dilution factor to obtain the sample FT4 concentration.

[0055] Experimental results: as shown in Table 1.

[0056] Table 1 Statistical analysis of FT4 and TSH levels

[0057]

[0058] Experimental results: Compared with the control group, the serum FT4 of mice gavaged with MMI decreased by 25.1%, and TSH increased by 31.7%, and the differences were statistically significant, indicating that the hypothyroidism model was successfully established. Compared with the CON group, the serum FT4 level of mice in the MMI group, SuHx+MMI group, and SuHx+MMI+L-T4 group was reduced, and the TSH level was increased, and the results showed statistical differences (P<0.05); compared with the SuHx+MMI group, the serum FT4 level of mice in the SuHx+MMI+L-T4 group was increased, and the TSH level was decreased, and the results showed statistical differences (P<0.05); There was no statistically significant difference in the serum FT4 and TSH levels between the SuHx group and the CON group (P>0.05).

[0059] 4. Pulmonary hypertension detection

[0060] 1. Right ventricular systolic pressure detection

[0061] After the ultrasonic measurement, the body weight (BW) of the mouse was weighed and recorded, and the mouse was anesthetized by intraperitoneal injection of chloral hydrate. The mouse was fixed on a mouse board in a supine position, the hair on the right side of the neck was shaved, the skin was incised along the right side of the neck, the right common jugular vein was bluntly separated, the distal end of the vein was ligated with cotton thread, the common jugular vein was lifted, a "V"-shaped incision was cut toward the ventricle, and a micro-tip pressure catheter was inserted into the right common jugular vein and connected to the Powerlab physiological recorder through a pressure sensor. The catheter was sent to the right ventricle, and a ventricular wave with a large amplitude could be seen on the display of the Powerlab physiological recorder. After stabilization for 1 minute, the right ventricular systolic pressure (RVSP) was measured by the displayed waveform curve and pressure value.

[0062] Experimental results: Figure 2 As shown. The right ventricular systolic pressure (RVSP) measured by right cardiac catheter in mice with pulmonary hypertension and hypothyroidism was higher than that in mice in the control group. Compared with the CON group, the increase in RVSP in the MMI group was not significant, and there was no statistical difference, while the RVSP in the SuHx group was significantly increased, and the results showed statistical differences (P<0.01); compared with the SuHx group, the RVSP in the SuHx+MMI group was significantly increased, and the results showed statistical differences (P<0.01); compared with the SuHx+MMI group, the RVSP in the SuHx+MMI+L-T4 group was reduced, and the results showed statistical differences (P<0.05).

[0063] 2. PAT and PAT / PET testing

[0064] Echocardiograms of mice were recorded using an ultra-high-resolution small animal ultrasound imaging system (Vevo 3100LT Visualsonics) with a probe frequency of 30 MHz. Pulmonary hemodynamics and right heart function were evaluated according to the references ([1] Zhu Z., Godana D., Li A., et al. Echocardiographic assessment of right ventricular function in experimental pulmonary hypertension. Pulmonary circulation. 2019, 9(2): 2045894019841987. [2] Kohut A., Patel N., Singh H. Comprehensive Echocardiographic Assessment of the Right Ventricle in Murine Models. J Cardiovasc Ultrasound. 2016, 24(3): 229-38.). The chest hair of mice was removed with depilatory cream. After successful anesthesia with 3% isoflurane, the mice were fixed on a preheated 37°C imaging platform, and the limbs were coated with electrocardiogram leads. When the heart rate was stable at 400-500 beats / min, echocardiography was performed and the heart rate (HR) of each mouse was recorded. The Doppler signal of pulmonary valve blood flow was recorded in the short axis section of the left ventricle by pulsed Doppler ultrasound, and the pulmonary artery acceleration time (PAT) and pulmonary ejection time (PET) were measured.

[0065] Experimental results: Figure 3 As shown. The PAT / PET of mice in the pulmonary hypertension combined with hypothyroidism group was lower than that of mice in the control group. Compared with CON, the PAT and PAT / PET values ​​of the SuHx group were lower, and the results showed statistical differences (P<0.01); compared with the SuHx group, the PAT (P<0.01) and PAT / PET (P<0.05) values ​​of the SuHx+MMI group were lower; compared with the SuHx+MMI group, the PAT and PAT / PET values ​​of the SuHx+MMI+L-T4 group were higher, and the results showed statistical differences (P<0.01). The MMI group and the CON group did not show statistically significant differences in the above indicators.

[0066] 3. HE staining

[0067] (1) Experimental preparation

[0068] ① Reagent preparation: prepare hematoxylin stain, eosin stain, gradient alcohol, xylene, neutral gum, etc.

[0069] ② Slice preparation: Slice the previously embedded mouse lung tissue paraffin block (slice the largest surface of one lung lobe, cutting as many blood vessels as possible), usually with a thickness of 4 to 6 μm.

[0070] (2) HE staining steps

[0071] ① Dewaxing and hydration: Dewax the sections in xylene, and then hydrate them in gradient alcohol.

[0072] ②Hematoxylin staining: Place the sections in hematoxylin staining solution and allow them to be fully stained for 10 minutes.

[0073] ③ Rinse and differentiate: Rinse the slices with tap water to remove excess dye, and then differentiate them with 1% hydrochloric acid alcohol.

[0074] ④ Rebluing: Place the slices in a weakly alkaline aqueous solution to rebluing the cell nuclei, making them appear blue.

[0075] ⑤Eosin staining: Immerse the sections in eosin staining solution for 3 minutes.

[0076] ⑥ Dehydration and transparency: Dehydrate again with gradient alcohol, and then transparentize with xylene.

[0077] ⑦ Sealing: Add neutral gum on the slice and cover with a coverslip to seal.

[0078] (3) Morphological observation

[0079] Pulmonary arterioles close to alveolar tissue were identified under an optical microscope and images (outer diameter 50-200 μm) were collected. Image analysis software Image J was used to measure the lumen area (LA) and total vascular area (TA), and the pulmonary vascular wall area index (wall area%, WA%) was calculated, WA% = (TA-LA) / TA×100%.

[0080] Experimental results: Figure 4HE staining results of lung tissue showed that compared with the CON group, the lung tissue of mice in the MMI group showed no obvious pathological abnormalities, while the other groups showed different degrees of pulmonary vascular wall thickening and lumen narrowing, which was consistent with the typical pathological characteristics of pulmonary vascular remodeling; compared with the SuHx group, the pulmonary vascular wall thickening of mice in the SuHx+MMI group was more prominent, and the degree of lumen stenosis was aggravated, and some were even close to occlusion; compared with the SuHx+MMI group, the pathological manifestations of pulmonary vascular wall thickening and lumen stenosis of mice in the SuHx+MMI+L-T4 group were significantly alleviated.

[0081] 4. Masson staining

[0082] (1) Experimental preparation

[0083] ① Reagent preparation: prepare the relevant reagents for Masson staining, including Weigert iron hematoxylin stain, acid fuchsin stain, phosphomolybdic acid solution, aniline blue stain, etc.

[0084] ② Slice preparation: Slice the paraffin block of mouse lung tissue (slice the largest surface of one lung lobe, cutting as many blood vessels as possible), and the slice thickness is usually 4 to 6 μm.

[0085] (2) Masson staining steps

[0086] ① Dewaxing and hydration: Dewax the sections in xylene, and then hydrate them in gradient alcohol.

[0087] ②Weigert iron hematoxylin staining: Immerse the sections in Weigert iron hematoxylin staining solution for 1 minute.

[0088] ③ Rinse and differentiate: Rinse the slices with tap water and then differentiate with 1% hydrochloric acid alcohol.

[0089] ⑤ Acid fuchsin staining: Immerse the sections in acid fuchsin staining solution for staining.

[0090] ⑥ Phosphomolybdic acid differentiation: Use phosphomolybdic acid solution to differentiate and remove excess acid fuchsin.

[0091] ⑦ Aniline blue staining: Immerse the sections in 2.5% aniline blue solution for 15 seconds.

[0092] ⑧ Dehydration and transparency: Dehydrate again with graded alcohol, then transparentize with xylene.

[0093] ⑨ Sealing: Add neutral gum on the slice and cover with a coverslip to seal.

[0094] (3) Morphological observation

[0095] Under an optical microscope, look for pulmonary arterioles close to alveolar tissue and collect images (outer diameter 50-200μm), observe the distribution and proliferation of collagen fibers around pulmonary blood vessels, and assess the degree of pulmonary vascular fibrosis based on the color and density of collagen fibers. The more collagen fibers proliferate and the darker the color, the more severe the fibrosis. At the same time, observe the morphology and structure of the blood vessels to see if there are any structural changes caused by fibrosis.

[0096] Experimental results: The collagen fibers in the lung tissue of the CON group mice were evenly distributed, with light staining and less amount, and the thickness of the pulmonary vessels was normal; compared with the CON group, there were many disorderly proliferating collagen fibers in the adventitia and surrounding tissues of the pulmonary vessels of the SuHx group mice, the blue-stained area was enlarged and the color was deepened, and the pulmonary vascular wall was thickened and the lumen was narrowed; compared with the SuHx group, the collagen fibers in the SuHx+MMI group mice were more deposited, the wall thickness increased, and the lumen was narrower; compared with the SuHx+MMI group, the collagen fibers in the SuHx+MMI+L-T4 group mice were significantly improved, and the wall thickening and lumen narrowing phenomena were improved. These observations indicate that the SuHx group mice showed pulmonary vascular remodeling, hypothyroidism aggravated the above manifestations, and L-T4 intervention could improve the pulmonary vascular pathological manifestations.

[0097] It can be seen from the above examples that the present invention successfully established a stable mouse model of hypothyroidism combined with pulmonary hypertension by combining drug intervention and hypoxic feeding.

[0098] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for constructing a mouse model of hypothyroidism combined with pulmonary hypertension, characterized in that: The following steps are involved: 1) The hypothyroidism mouse model was obtained by gavage of methimazole in mice and keeping them in a normoxic environment; 2) The hypothyroidism mouse model was continued to be gavaged with methimazole, the vascular endothelial growth factor inhibitor Su5416 was continuously injected subcutaneously, and the mouse model with hypothyroidism and pulmonary hypertension was obtained by raising the mouse in a hypoxic environment.

2. The construction method according to claim 1, characterized in that: The mice are C57BL / 6 mice.

3. The construction method according to claim 1, characterized in that: The intragastric administration amount of methimazole in step 1) is 30-50 mg / kg / d; the intragastric administration time of methimazole is 3-5 weeks.

4. The construction method according to claim 1, characterized in that: In step 2), the intragastric administration amount of methimazole is 30-50 mg / kg / d; the intragastric administration time of methimazole is 3-4 weeks.

5. The construction method according to claim 1, characterized in that: The injection amount of the vascular endothelial growth factor inhibitor Su5416 in step 2) is 20 mg / kg / w.

6. The construction method according to claim 1 or 5, characterized in that: The injection time of the vascular endothelial growth factor inhibitor Su5416 is 3 to 4 weeks.

7. The construction method according to claim 1, characterized in that: The oxygen concentration of the hypoxic environment in step 2) is 9-11%.

8. Use of the mouse model of hypothyroidism combined with pulmonary hypertension constructed by the construction method according to any one of claims 1 to 7 in pathological research of hypothyroidism combined with pulmonary hypertension or in vitro drug testing and screening.

Citation Information

Patent Citations

  • Multivalent and monovalent multispecific complexes and their uses

    CN106432506A

  • Small RNA (Ribonucleic Acid) medicine for preventing and treating inflammatory related diseases and combination thereof

    CN118530991A

  • Inhibitors of Ccr9 Activity

    US20080275114A1

  • Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by Anti-cancer therapy

    WO2018185516A1

Cited By

  • Construction method of mouse model with hypothyroidism and depression

    CN121100866A